Table 2.
Four-year rates for DFS, DDFS, and OS according to subgroups.
| DFS rate (95% CI) | DDFS rate (95% CI) | OS rate (95% CI) | |
|---|---|---|---|
| Overall | 89.6% (88.1%, 90.9%) | 92.5% (91.2%, 93.6%) | 95.2% (94.2%, 96.1%) |
| Subgroups | |||
| cT1 | 91.2% (87.9%, 93.6%) | 93.9% (91.0%, 95.8%) | 96.1% (93.7%, 97.7%) |
| cT2 | 90.2% (88.3%, 91.8%) | 93.4% (91.7%, 94.7%) | 96.0% (94.6%, 97.0%) |
| cT3/4 | 85.7% (81.5%, 89.0%) | 88.0% (84.1%, 91.0%) | 91.8% (88.4%, 94.3%) |
| cN0 | 92.2% (90.4%, 93.7%) | 95.0% (93.4%, 96.2%) | 96.9% (95.6%, 97.8%) |
| cN+ | 86.5% (83.9%, 88.6%) | 89.5% (87.3%, 91.4%) | 93.3% (91.4%, 94.8%) |
| Lobular tumor type | 82.6% (70.7%, 90.0%) | 87.4% (76.4%, 93.5%) | 90.6% (80.3%, 95.7%) |
| Non-lobular tumor type | 89.8% (88.3%, 91.1%) | 92.6% (91.3%, 93.8%) | 95.4% (94.3%, 96.3%) |
| HER2-/HR + | 91.9% (88.6%, 94.3%) | 94.7%(91.8%, 96.5%) | 97.0%(94.7%, 98.3%) |
| TNBC | 90.2% (87.8%, 92.2%) | 92.9%(90.8%, 94.5%) | 94.6%(92.6%, 96.0%) |
| HER2 + /HR + | 89.0% (85.2%, 91.8%) | 91.4%(88.0%, 93.9%) | 96.8%(94.3%, 98.2%) |
| HER2 + /HR- | 87.9% (84.0%, 90.9%) | 91.2%(87.6%, 93.7%) | 94.2%(91.2%, 96.2%) |
| Ki-67 ≤ 20% | 89.9%(85.0%, 93.2%) | 91.9%(87.4%, 94.8%) | 96.5%(93.1%, 98.2%) |
| Ki-67 > 20% | 89.9%(87.8%, 91.7%) | 92.9%(91.1%, 94.4%) | 95.5%(93.9%, 96.7%) |
| Grade 1/2 | 88.1%(85.4%, 90.3%) | 91.0%(88.6%, 92.9%) | 95.1%(93.2%, 96.5%) |
| Grade 3 | 90.6%(88.7%, 92.2%) | 93.1%(91.5%, 94.4%) | 95.2%(93.7%, 96.3%) |
| Age ≤ 40 years | 90.1%(86.9%, 92.6%) | 93.6%(90.9%, 95.5%) | 95.6%(93.3%, 97.2%) |
| Age 41–59 years | 89.1%(87.1%, 90.8%) | 92.1%(90.3%, 93.5%) | 95.2%(93.8%, 96.3%) |
| Age ≥ 60 years | 90.8%(86.9%, 93.5%) | 92.4%(88.8%, 94.9%) | 94.7%(91.5%, 96.7%) |
| BMI < 25 | 90.4%(88.3%, 92.1%) | 94.0%(92.3%, 95.3%) | 95.9%(94.5%, 97.0%) |
| BMI 25–29 | 87.7%(84.7%, 90.1%) | 89.9%(87.1%, 92.1%) | 94.2%(91.9%, 95.8%) |
| BMI ≥ 30 | 90.7%(86.8%, 93.5%) | 92.5%(88.9%, 94.9%) | 95.0%(91.8%, 97.0%) |
| Premenopausal | 88.7%(86.7%, 90.4%) | 92.3%(90.6%, 93.8%) | 95.3%(93.9%, 96.4%) |
| Postmenopausal | 90.8%(88.5%, 92.7%) | 92.6%(90.5%, 94.3%) | 95.1%(93.3%, 96.5%) |
| ≤6 planned CT cycles | 89.1%(85.7%, 91.8%) | 91.5%(88.4%, 93.9%) | 93.7%(90.8%, 95.7%) |
| >6 planned CT cycles | 89.7%(88.1%, 91.2%) | 92.8%(91.3%, 94.0%) | 95.7%(94.5%, 96.6%) |
| Complete response after 2–4 cycles | 91.7%(88.4%, 94.2%) | 93.4%(90.4%, 95.6%) | 94.2%(91.3%, 96.2%) |
| Partial response after 2–4 cycles | 89.0%(87.1%, 90.6%) | 92.2%(90.6%, 93.5%) | 95.1%(93.8%, 96.2%) |
| Stable disease after 2–4 cycles | 90.0% (84.1%, 93.8%) | 93.3%(88.2%, 96.2%) | 97.5% (93.5%, 99.1%) |
| Progress after 2–4 cycles | 84.7%(59.7%, 94.8%) | 84.1%(58.3%, 94.6%) | 94.7%(68.1%, 99.2%) |
| ypT0 | 90.8% (89.2%, 92.2%) | 93.0% (91.6%, 94.1%) | 95.4% (94.2%, 96.3%) |
| ypTis | 84.5% (80.3%, 87.9%) | 90.5% (86.9%, 93.1%) | 94.8% (91.8%, 96.7%) |
BMI body mass index, DDFS distant disease-free survival, DFS disease-free survival, ER estrogen receptor, PgR progesterone receptor, HER2 human epidermal growth factor receptor 2, HR hormone receptor, OS overall survival, TNBC triple-negative breast cancer